Wedbush Reiterates Outperform on Nutrisystem

Wedbush is out with its report today on Nutrisystem NTRI, reiterating Outperform. In its report, Wedbush writes, "Given an improved competitive outlook, lower fixed-cost base, and benefit from new products and programs, we believe shares of NTRI should trade relatively in line to the peer-group average. Thus, using an EV/ 2012E EBITDA multiple of 8x, we generate our PT of $19." At the time of posting, shares of NTRI were trading pre-market at $12.75, down 0.62% from Monday's close.